FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
• By Jacqueline Fitton and Michael McCaughan
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Look for the FDA-CMS parallel review program to be extended via an announcement in the Federal Register later this year.
Centers for Medicare & Medicaid Services Coverage and Analysis Group Director Tamara Syrek Jensen indicated during the Food and Drug Law Institute annual meeting on April 21
